蚌埠医科大学
Bengbu Medical University
名字里带这所大学的医院合在一起算,再加上只署大学名称的论文和试验。
只反映研究活动,不代表医疗水平,也不是医疗建议。 使用说明
鼻咽癌
Nasopharyngeal carcinoma2021–2025年中国大陆共有 2,375 篇该病的 PubMed 英文论文,这里牵头了其中 8 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(23.4%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 8
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.2%
这些论文过半是实验室或动物研究。
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- miR-199a-5p inhibits malignant progression and enhances cisplatin sensitivity of nasopharyngeal carcinoma by targeting SLC1A5.
- Epigenetic regulation of TIPE3 in nasopharyngeal carcinoma and its impact on the hedgehog signaling pathway.
- PRDX3 promotes nasopharyngeal carcinoma tumor growth by regulating PINK1/Parkin pathway-dependent lipid peroxidation and mitochondrial dysfunction.
- The AXL-mediated modulation of myeloid-derived suppressor cells (MDSC) in nasopharyngeal carcinoma.
- Semisynthesis and anti-cancer properties of novel honokiol derivatives in human nasopharyngeal carcinoma CNE-2Z cells.
ClinicalTrials.gov 上的试验3
- Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE)
- A Study of BH009 in Head and Neck Squamous Cell Carcinoma and Ovarian Cancer
- Hemoglobin, Neutrophil to Lymphocyte Ratio and Platelet Count Improve Prognosis Prediction in Nasopharyngeal Carcinoma
食管鳞状细胞癌
Oesophageal squamous cell carcinoma2021–2025年中国大陆共有 2,923 篇该病的 PubMed 英文论文,这里牵头了其中 5 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(6.9%)相比。
- 牵头的开放试验
- 1
- 牵头的研究论文
- 5
- 牵头的试验
- 1
- 占中国试验的比例
- 0.2%
- 占全球论文的比例
- 0.1%
这些论文过半是实验室或动物研究。
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Angiotensin II and AGTR1 in ESCC Proliferation and Invasion: Insights from the JAK/STAT3 Pathway.
- Changes in PD-1 expression on T lymphocyte subsets and related immune indicators before and after definitive chemoradiotherapy for esophageal squamous cell carcinoma.
- Fbxo45 promotes the malignant development of esophageal squamous cell carcinoma by targeting GGNBP2 for ubiquitination and degradation.
- Clinicopathological significances of PLOD2, epithelial-mesenchymal transition markers, and cancer stem cells in patients with esophageal squamous cell carcinoma.
- The molecular mechanisms of the long noncoding RNA SBF2-AS1 in regulating the proliferation of oesophageal squamous cell carcinoma.
ClinicalTrials.gov 上的试验5
- Becotatug Vedotin in Combination With Immunotherapy and Multimodality Radiotherapy for Esophageal Squamous Cell Carcinoma in the Second-line or Later Setting
- Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.
- Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
- A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy
- A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma
肝细胞癌
Hepatocellular carcinoma2021–2025年中国大陆共有 14,765 篇该病的 PubMed 英文论文,这里牵头了其中 41 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(5.5%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 41
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.1%
这些论文过半是实验室或动物研究。
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Successful Liver Transplantation After Achieving Complete Clinical Remission of Hepatocellular Carcinoma With Combination Therapy of Immune Checkpoint Inhibitors and Targeted Agents: A Case Report.
- Real-world status, efficacy and prognosis analysis of first-line treatment for unresectable hepatocellular carcinoma in patients treated at multiple centres.
- The application of dynamic contrast-enhanced ultrasonography in immediate distinguishing residual tumour from benign periablational enhancement after hepatocellular carcinoma radiofrequency ablation.
- Body composition predicts prognosis of hepatocellular carcinoma patients undergoing immune checkpoint inhibitors.
- Efficacy and Prognostic Factors of Regorafenib in the Treatment of BCLC Stage C Hepatocellular Carcinoma After Failure of the First-Line Therapy.
ClinicalTrials.gov 上的试验6
- A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC
- Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
- A Clinical Trial Assessing the Safety and Efficacy of Biodegradable Magnesium Embolic Microspheres for Primary Hepatocellular Carcinoma
- Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
- Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
- A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)
胃癌
Stomach cancer2021–2025年中国大陆共有 9,782 篇该病的 PubMed 英文论文,这里牵头了其中 31 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(3.9%)相比。
- 牵头的开放试验
- 1
- 牵头的研究论文
- 31
- 牵头的试验
- 2
- 占中国试验的比例
- 0.1%
- 占全球论文的比例
- 0.1%
这些论文过半是实验室或动物研究。
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- The quantification and clinical analysis of depression and anxiety in patients undergoing Da Vinci robot-assisted radical gastrectomy and open radical gastrectomy.
- Esophagojejunal Anastomosis After Totally Laparoscopic Total Gastrectomy: π-shaped Versus Reverse Puncture Device Anastomosis.
- Dynamic variations in peripheral blood indices and their association with efficacy and adverse reactions of pd- 1 inhibitor combined chemotherapy in patients with advanced gastric cancer.
- Baseline Inflammatory Burden Index Predicts Primary Resistance to Combinations of ICIs With Chemotherapy in Patients With HER-2-Negative Advanced Gastric Cancer.
- Expression Level of Small Nuclear Ribonucleoprotein D1 in Gastric Cancer and Its Effect on Prognosis.
ClinicalTrials.gov 上的试验6
- Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer
- A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
- A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
- A Study of HER2 Tumor Vaccine in Patients With Her-2 Positive Gastric/GEJ Adenocarcinoma Esophagogastric
- Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
- Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric Cancer
肝母细胞瘤
Hepatoblastoma2021–2025年中国大陆共有 154 篇该病的 PubMed 英文论文,这里牵头了其中 2 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(13.6%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 2
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.4%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
骨肉瘤
Osteosarcoma2021–2025年中国大陆共有 2,257 篇该病的 PubMed 英文论文,这里牵头了其中 0 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(4.3%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 0
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.0%
多发性骨髓瘤
Multiple myeloma2021–2025年中国大陆共有 1,676 篇该病的 PubMed 英文论文,这里牵头了其中 5 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(4.8%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 5
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.05%
这些论文过半是实验室或动物研究。
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- VRd vs. VPd as induction therapy in high risk newly diagnosed multiple myeloma.
- Downregulation of CLEC2 Facilitates the Proliferation and Migration of Multiple Myeloma Cells via Regulating HIF-1α-Mediated Ferroptosis.
- MiR-155-5p Inhibits Multiple Myeloma Cell Malignancy and Tumorigenesis by Targeting JARID2 and Inactivating the TGFβ/SMAD2 Signaling.
- Circ_0005615 enhances multiple myeloma progression through interaction with EIF4A3 to regulate MAP3K4 m6A modification mediated by ALKBH5.
- CircRNA circ_0001821 predicts an unfavorable prognosis and promotes the proliferation of multiple myeloma.
ClinicalTrials.gov 上的试验6
- Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
- A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies
- A Study Evaluating Safety, Tolerability and Clinical Activity of FHND6091 in Patients With Multiple Myeloma
- Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)
- TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
血友病 A
Haemophilia A2021–2025年中国大陆共有 272 篇该病的 PubMed 英文论文,这里牵头了其中 4 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(15.8%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 4
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.1%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文4
- Inhibition of CIRBP as a Novel Strategy to Alleviate Chondrocyte Ferroptosis in Haemophilic Arthropathy.
- Identification of Iron Overload-Associated Biomarkers in the Synovium of Haemophilic Arthropathy.
- Interleukin-10 Mitigates Chondrocyte Ferroptosis Associated With Haemophilic Arthropathy via Modulation of the STAT3 Signalling Pathway.
- Identification and Analysis of Mitochondria-Related Proteins in Haemophilic Arthritis Synovial Membranes Based on Proteomic Analysis.
肌萎缩侧索硬化症
Amyotrophic lateral sclerosis2021–2025年中国大陆共有 779 篇该病的 PubMed 英文论文,这里牵头了其中 2 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(8.3%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 2
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.03%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
IgA 肾病
IgA nephropathy2021–2025年中国大陆共有 736 篇该病的 PubMed 英文论文,这里牵头了其中 2 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(9.4%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 2
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.1%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。